Updated 23/12/2020. Graduated in Biology. Science PhD (UAM-CSIC, 2000). In the field of applied dermatology since 2001 and epidermolysis bullosa diagnosis since 2007, I have participated in 29 projects being the Principal Investigator (PI) in 7 (4 competitive national projects and 3 funded by patient associations). Within the technological field is worthy to mention the development of two orphan drugs for EB and the application for a patent. The latest orphan drug (EU/ 3/20/2253), combining tissue engineering and gene editing, has been developed within MULTITEREB project (SAF2017-86810-R; co-PI). I have contributed to clinical translation by the treatment of patients in the context of compassionate use and by participating in 4 clinical trials (CT). I am coordinating one of this CT (NCT04153630) to analyse the safety and efficacy of intravenous administration of haploidentical mesenchymal cells in RDEB. We are also correlating the clinical results with omic data (ACCI-2017-04) and studying through qualitative methods (interviews and recordings) the patient's point of view. I am directing the PhD theses of a dermatologist and a research nurse, which reflects the applied and interdisciplinary nature of my research. As part of the diagnostic activity, disclosing the first epidemiological data on EB in Spain, causal mutations and phenotypic correlations, I have collaborated in the generation of the Spanish EB registry and an international clinical guide. Awarded by DEBRA-Spain.